Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 721-728

  Mankaï, Amani ^a,c   Buhé, Virginie ^a   Hammadi, Mariam ^a   Youinou, Pierre ^a,b   Ghedira, Ibtissem ^c   Berthou, Christian ^a,b   Bordron, Anne ^a  

^a Universite de Brest   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

CD20; Chronic lymphocytic leukemia; CpG; PU.1 transcription factor

Indexed keywords

ALPHA INTERFERON; CD20 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 21; INTERLEUKIN 3; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; RITUXIMAB; TRANSCRIPTION FACTOR PU 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIGEN EXPRESSION; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; NUCLEOTIDE SEQUENCE; UPREGULATION; WESTERN BLOTTING;

EID: 69949160771     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04614.x     Document Type: Conference Paper

References (33)

1. Gordron A. A. Mankäi B. Bendaoud, et al. 2007. B cell-ablative therapy: where are we now? Int. J. Immunopathol. Pharmacol. 20: 655-659.
2. Dass, S., A.C. Rawstron, E.M. Vital, et al. 2008. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58: 2993-2999.
3. Isaksen, K., R. Jonsson & R. Omdal. 2008. Anti-CD20 treatment in primary Sjögren's syndrome. Scand. J. Immunol. 68: 554-564.
4. Beum, P.V., A.D. Kennedy & R.P. Taylor. 2004. Three new assays for rituximab based on its im-munological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lym-phomas. J. Immunol. Methods 289: 97-109.
5. Yamagata, K., K. Onizawa, H. Kojima, et al. 2008. Treatment of localized oral MALT lymphoma by rituximab: a case report. Oral. Maxillofac. Surg. 12: 227-230.
6. Held, G., V. Pöschel & M. Pfreundschuh. 2006. Rit-uximab for the treatment of diffuse large B-cell lym-phomas. Expert Rev. Anticancer Ther. 6: 1175-1186. (Pubitemid 44304686)
7. McLaughlin, P., A.J. Grillo-López, B.K. Link, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16: 2825-2833.
8. Huhn, D., C. von Schilling, M. Wilhelm, et al. 2001. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98: 1326-1331.
9. Byrd, J.C., S. Kitada, I.W. Flinn, et al. 2002. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apop-tosis induction. Blood 99: 1038-1043.
10. Cragg, M.S., S.M. Morgan, H.T. Chan, et al. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101: 1045-1052.
11. Uchida, J., Y. Hamaguchi, J.A. Oliver, et al. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
12. Ginaldi, L., M. De Martinis, E. Matutes, et al. 1998. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J. Clin. Pathol. 51: 364-369.
13. Mankäi, A., A. Bordron, Y. Renaudineau, et al. 2008. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lym-phocytic leukemia B cells. Cancer Res. 68: 7512-7519.
14. Venugopal, P., S. Sivaraman, X.K. Huang, et al. 2000. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk. Res. 24: 411-415. (Pubitemid 30227241)
15. Wang J.M., M.Z. Lai & H.F Yang-Yen. 2003. Interleukin-3 stimulation of mcl-1 gene transcription involves activation of the PU.1 transcription factor through a p38 mitogen-activated protein kinase-dependent pathway. Mol. Cell. Biol. 23: 1896-1909.
16. Sivaraman, S., P. Venugopal, R. Ranganathan, et al. 2000. Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines. Cell. Mol. Ther. 6: 81-87. (Pubitemid 30954058)
17. Hartmann, G. & A.M. Krieg. 2000. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164: 944-953.
18. Decker, T., F. Schneller, T. Sparwasser, et al. 2000. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95: 999-1006.
19. Jahrsdörfer, B., G. Hartmann, E. Racila, et al. 2001. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukoc. Biol. 69: 81-88.
20. Secchiero, P., E. Melloni, M. Tiribelli, et al. 2008. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. J. Leukoc. Biol. 83: 434-437.
21. Kim, H.A., H.M. Ko & H.W. Ju. 2009. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells. Cancer Lett. 274: 160-164.
22. Xiong, Z., S. Gharagozlou, I. Vengco, et al. 2008. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin. Cancer Res. 14: 5484-5493.
23. Matutes, E., K. Owusu-Ankomah, R. Morilla, et al. 1994. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8: 1640-1645.
24. Binet, J.L., A. Auquier, G. Dighiero, et al. 1981. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198-206.
25. Lapalombella, R., B. Yu, G. Triantafillou, et al. 2008. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lym-phocytic leukemia cells. Blood 112: 5180-5189.
26. Sivaraman, S., C.G. Deshpande, R. Ranganathan, et al. 2000. Tumor necrosis factor modulates CD20 expression on cells from chronic lymphocytic leukemia: a new role for TNF alpha? Microsc. Res. Tech . 50: 251-257.
27. Chow, K.U., B. Schneider, P.S. Mitrou, et al. 2001. Influence of various cytokines on the expression of CD20 on the surface of CLL-cells in vitro. Leuk. Res. 25: 99-100.
28. Wojciechowski, W., H. Li, S. Marshall, et al.2005. Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms. J. Immunol. 174: 7859-7868.
29. Dye, J.R., A. Palvanov, B. Guo, et al. 2007. B cell receptor cross-talk: exposure to lipopolysaccharide induces an alternate pathway for B cell receptor-induced ERK phosphorylation and NF-kappa B activation. J. Immunol. 179: 229-235.
30. Peng, S.L. 2005. Signaling in B cells via Toll-like receptors. Curr. Opin. Immunol. 17: 230-236.
31. Mathas, S., A. Rickers, K. Bommert, et al. 2000. Anti-CD20-and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 60: 7170-7176.
32. Novak, A.J., R.J. Bram, N.E. Kay, et al. 2002. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 100: 2973-2979.
33. Meyer zum Büschenfelde, C., Y. Feuerstacke, K.S. Götze, et al. 2008. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment. Cancer Res. 68: 5414-5422.